Kancera AB (publ) (KAN.ST)
SEK 1.22
(9.09%)
SEK 1.22
(9.09%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 65.64 Million SEK | -45.63% |
| 2022 | 120.73 Million SEK | -9.5% |
| 2021 | 133.4 Million SEK | 60.53% |
| 2020 | 83.1 Million SEK | 87.37% |
| 2019 | 44.35 Million SEK | -2.59% |
| 2018 | 45.53 Million SEK | -11.11% |
| 2017 | 51.22 Million SEK | -29.86% |
| 2016 | 73.03 Million SEK | 166.43% |
| 2015 | 27.41 Million SEK | -24.74% |
| 2014 | 36.42 Million SEK | 41.99% |
| 2013 | 25.64 Million SEK | 37.38% |
| 2012 | 18.67 Million SEK | -53.02% |
| 2011 | 39.74 Million SEK | 183.6% |
| 2010 | 14.01 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 123.33 Million SEK | 87.88% |
| 2024 Q2 | 95.63 Million SEK | -22.45% |
| 2023 Q2 | 91.43 Million SEK | -12.7% |
| 2023 Q4 | 65.64 Million SEK | -16.19% |
| 2023 Q1 | 104.73 Million SEK | -13.26% |
| 2023 FY | 65.64 Million SEK | -45.63% |
| 2023 Q3 | 78.32 Million SEK | -14.34% |
| 2022 Q1 | 122.93 Million SEK | -7.85% |
| 2022 Q3 | 94.27 Million SEK | -13.36% |
| 2022 FY | 120.73 Million SEK | -9.5% |
| 2022 Q2 | 108.81 Million SEK | -11.49% |
| 2022 Q4 | 120.73 Million SEK | 28.07% |
| 2021 Q4 | 133.4 Million SEK | -8.52% |
| 2021 Q2 | 154.13 Million SEK | 99.18% |
| 2021 Q3 | 145.83 Million SEK | -5.39% |
| 2021 FY | 133.4 Million SEK | 60.53% |
| 2021 Q1 | 77.38 Million SEK | -6.88% |
| 2020 Q2 | 92.07 Million SEK | 63.78% |
| 2020 FY | 83.1 Million SEK | 87.37% |
| 2020 Q1 | 56.21 Million SEK | 26.75% |
| 2020 Q3 | 96.64 Million SEK | 4.96% |
| 2020 Q4 | 83.1 Million SEK | -14.01% |
| 2019 FY | 44.35 Million SEK | -2.59% |
| 2019 Q3 | 36.34 Million SEK | 0.01% |
| 2019 Q2 | 36.34 Million SEK | -14.39% |
| 2019 Q1 | 42.45 Million SEK | -6.77% |
| 2019 Q4 | 44.35 Million SEK | 22.03% |
| 2018 FY | 45.53 Million SEK | -11.11% |
| 2018 Q4 | 45.53 Million SEK | -22.55% |
| 2018 Q2 | 75.05 Million SEK | 84.68% |
| 2018 Q1 | 40.63 Million SEK | -20.67% |
| 2018 Q3 | 58.78 Million SEK | -21.67% |
| 2017 Q1 | 63.93 Million SEK | -12.46% |
| 2017 Q3 | 68.99 Million SEK | -9.32% |
| 2017 Q2 | 76.08 Million SEK | 19.01% |
| 2017 FY | 51.22 Million SEK | -29.86% |
| 2017 Q4 | 51.22 Million SEK | -25.76% |
| 2016 Q3 | 77.1 Million SEK | -6.3% |
| 2016 FY | 73.03 Million SEK | 166.43% |
| 2016 Q4 | 73.03 Million SEK | -5.28% |
| 2016 Q2 | 82.28 Million SEK | 237.51% |
| 2016 Q1 | 24.38 Million SEK | -11.05% |
| 2015 Q4 | 27.41 Million SEK | -26.72% |
| 2015 Q1 | 31.87 Million SEK | -12.48% |
| 2015 FY | 27.41 Million SEK | -24.74% |
| 2015 Q2 | 41.13 Million SEK | 29.05% |
| 2015 Q3 | 37.4 Million SEK | -9.07% |
| 2014 Q2 | 43.85 Million SEK | 42.23% |
| 2014 FY | 36.42 Million SEK | 41.99% |
| 2014 Q4 | 36.42 Million SEK | -11.47% |
| 2014 Q3 | 41.13 Million SEK | -6.18% |
| 2014 Q1 | 30.83 Million SEK | 20.2% |
| 2013 Q3 | 13.05 Million SEK | -15.76% |
| 2013 Q4 | 25.64 Million SEK | 96.41% |
| 2013 FY | 25.64 Million SEK | 37.38% |
| 2013 Q1 | 16.45 Million SEK | -11.87% |
| 2013 Q2 | 15.5 Million SEK | -5.77% |
| 2012 Q3 | 21.85 Million SEK | -29.28% |
| 2012 Q4 | 18.67 Million SEK | -14.58% |
| 2012 FY | 18.67 Million SEK | -53.02% |
| 2012 Q2 | 30.9 Million SEK | -2.21% |
| 2012 Q1 | 31.6 Million SEK | -20.48% |
| 2011 Q2 | 48.33 Million SEK | -8.05% |
| 2011 Q3 | 46.26 Million SEK | -4.29% |
| 2011 Q4 | 39.74 Million SEK | -14.09% |
| 2011 FY | 39.74 Million SEK | 183.6% |
| 2011 Q1 | 52.56 Million SEK | 275.13% |
| 2010 Q4 | 14.01 Million SEK | 46.7% |
| 2010 FY | 14.01 Million SEK | 0.0% |
| 2010 Q3 | 9.55 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 44.582% |
| Ziccum AB (publ) | 14.97 Million SEK | -338.438% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -227.544% |
| BioArctic AB (publ) | 1.18 Billion SEK | 94.466% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -5.236% |
| Mendus AB (publ) | 755.95 Million SEK | 91.317% |
| Genovis AB (publ.) | 288.85 Million SEK | 77.275% |
| Intervacc AB (publ) | 259.61 Million SEK | 74.715% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -56.446% |
| Active Biotech AB (publ) | 44 Million SEK | -49.189% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 76.451% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -5.617% |
| Aptahem AB (publ) | 63.02 Million SEK | -4.154% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 86.772% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 81.316% |
| Fluicell AB (publ) | 9.34 Million SEK | -602.816% |
| Saniona AB (publ) | 64.14 Million SEK | -2.339% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -95.354% |
| Biovica International AB (publ) | 131.4 Million SEK | 50.046% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -23.89% |
| AcouSort AB (publ) | 34.51 Million SEK | -90.198% |
| Xintela AB (publ) | 18.39 Million SEK | -256.852% |
| Abliva AB (publ) | 87.49 Million SEK | 24.979% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 91.365% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 94.784% |
| OncoZenge AB (publ) | 20.34 Million SEK | -222.729% |
| Amniotics AB (publ) | 26.08 Million SEK | -151.641% |
| 2cureX AB (publ) | 16.62 Million SEK | -294.845% |
| CombiGene AB (publ) | 120.61 Million SEK | 45.575% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -980.188% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 96.546% |
| Camurus AB (publ) | 1.9 Billion SEK | 96.559% |
| Corline Biomedical AB | 100.1 Million SEK | 34.426% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 62.939% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 53.311% |
| I-Tech AB | 152.44 Million SEK | 56.939% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 93.552% |
| Cyxone AB (publ) | 43.65 Million SEK | -50.368% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 16.582% |
| Biosergen AB | 7.2 Million SEK | -811.582% |
| Cantargia AB (publ) | 223.71 Million SEK | 70.657% |
| NextCell Pharma AB | 81.28 Million SEK | 19.246% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 91.422% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -117.555% |
| Nanologica AB (publ) | 77.42 Million SEK | 15.222% |
| SynAct Pharma AB | 228.01 Million SEK | 71.212% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -145.275% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -202.462% |
| LIDDS AB (publ) | 17.65 Million SEK | -271.81% |
| Lipum AB (publ) | 12.11 Million SEK | -442.056% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 95.312% |
| Alzinova AB (publ) | 123.18 Million SEK | 46.714% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 72.463% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -676.381% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 22.979% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -341.476% |
| Simris Alg AB (publ) | 174.55 Million SEK | 62.393% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 69.755% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 89.955% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 24.611% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -130.262% |